EBAG9 Antibody

What is EBAG9 and why is it important in cancer research?

EBAG9 (estrogen receptor-binding fragment-associated gene 9) is a highly conserved protein that was initially identified as a potential tumor-associated antigen. Contrary to early assumptions, EBAG9 is not tumor-specific but is expressed in various normal tissues. Its significance in cancer research stems from its potential role in modulating immune responses in the tumor microenvironment. EBAG9 has been found to suppress T-cell infiltration into tumors in vivo, while in host immune cells, it functions as a limiter for T-cell cytotoxicity, suggesting a dual role in promoting immune escape mechanisms . Animal studies with EBAG9 knockout mice crossed with transgenic adenocarcinoma of the mouse prostate (TRAMP) mice demonstrated that EBAG9 plays a crucial role in prostate cancer development, indicating its potential as a therapeutic target .

What is the difference between the 22-1-1 antibody and the Ab-1 anti-EBAG9 antibody?

The 22-1-1 monoclonal antibody and the Ab-1 anti-EBAG9 antibody recognize different antigens, despite being frequently used interchangeably in literature. The 22-1-1 antibody recognizes the O-linked glycan Tn (αGalNAc), which is a tumor-associated carbohydrate antigen, while Ab-1 specifically recognizes the EBAG9 protein . Immunohistochemical studies have demonstrated significant differences in staining patterns between these antibodies. For instance, 22-1-1 consistently stains secreted mucus from glandular tissues, while Ab-1 does not react with mucus. Additionally, in signet ring cell carcinomas, 22-1-1 strongly labels intracellular mucin, whereas these cells remain almost negative with Ab-1 . These distinctions are critical for researchers interpreting results from studies using these antibodies.

How can I verify the specificity of my anti-EBAG9 antibody?

To verify specificity of anti-EBAG9 antibodies, implement a multi-technique validation approach:

• Immunoblotting with positive and negative controls: Use cell lines with known EBAG9 expression levels (e.g., MCF-7 and Jurkat have high endogenous expression) alongside EBAG9 knockout samples .

• Immunohistochemistry comparison: Perform side-by-side staining with different anti-EBAG9 antibodies (e.g., Ab-1 and 22-1-1) on the same tissue sections to identify differential staining patterns that may indicate non-specific binding .

• Flow cytometry correlation: Compare surface expression patterns detected by flow cytometry with protein expression detected by immunoblotting to assess whether antibody reactivity corresponds to actual protein levels .

• Subcellular localization verification: Since EBAG9 is predominantly Golgi-localized, co-staining with Golgi markers like mannosidase II can confirm antibody specificity. Use Brefeldin A treatment, which disrupts Golgi structure, to observe expected relocalization of EBAG9 .

• Recombinant expression system: Transfect cells with EBAG9-GFP fusion constructs and compare localization patterns between the tagged protein and antibody staining .

What are the recommended methods for detecting EBAG9 expression in tissue samples?

For comprehensive detection of EBAG9 expression in tissue samples, a multi-methodological approach is recommended:

Immunohistochemistry (IHC): Use EBAG9-specific antibodies such as Ab-1 rather than 22-1-1, as the latter recognizes the Tn antigen rather than EBAG9 itself. For IHC protocols, fixation with 3-4% paraformaldehyde provides good morphological preservation while maintaining antigenicity. Include appropriate positive controls (tissues with known EBAG9 expression) and negative controls (EBAG9 knockout tissues or primary antibody omission) .

RT-PCR and qPCR: These techniques provide quantitative assessment of EBAG9 mRNA expression. Design primers specific to EBAG9 coding regions and validate them against known EBAG9 sequences to ensure specificity .

Western blotting: For protein extraction, use a buffer containing appropriate detergents (e.g., Triton X-100) to solubilize membrane-associated EBAG9. The characteristic double band pattern in immunoblots can help confirm EBAG9 identity .

Electron microscopy: For ultrastructural localization, immunogold labeling with anti-EBAG9 antibodies can precisely localize EBAG9 to the Golgi apparatus and associated vesicles. This approach requires ultrathin cryosections (approximately 70 nm) and specialized detection systems such as colloidal gold-conjugated secondary antibodies .

When reporting results, it is crucial to specify which antibody was used and to acknowledge the distinction between EBAG9 protein expression and Tn antigen expression to avoid misinterpretation of data.

How can I study the subcellular localization of EBAG9?

To accurately determine EBAG9 subcellular localization, employ these complementary approaches:

Confocal microscopy with marker co-localization: EBAG9 predominantly localizes to the Golgi apparatus. Transfect cells with EBAG9-GFP constructs and co-stain with Golgi markers such as mannosidase II (for cis/medial Golgi) and TGN38 (for trans-Golgi network). Analyze co-localization using appropriate software to calculate overlap coefficients .

Organelle disruption experiments: Treat cells with Brefeldin A (5 μg/ml) for various time points (15, 30, and 60 minutes) to disrupt the Golgi structure, and observe EBAG9 redistribution. Similarly, use nocodazole (10 μg/ml for 2 hours) to disassemble microtubules and observe effects on EBAG9 localization .

Electron microscopy: For ultrahigh resolution, perform immunogold labeling of EBAG9 in ultrathin cryosections (70 nm). Use cells stably transfected with EBAG9-GFP and detect with anti-GFP antibodies followed by gold-conjugated secondary antibodies. Process sections according to Tokuyasu methods and contrast with tungstosilicic acid hydrate/polyvinyl alcohol mixture .

Subcellular fractionation: Isolate cellular compartments through differential centrifugation and detect EBAG9 in each fraction by immunoblotting. Compare distribution with known Golgi markers as positive controls and markers of other organelles as negative controls.

Live-cell imaging: For dynamic studies, monitor EBAG9-GFP in living cells over time to observe trafficking patterns and response to stimuli such as growth factors or stress conditions.

What experimental controls should be included when studying EBAG9 function?

When investigating EBAG9 function, include these essential controls:

Expression controls: Validate EBAG9 expression levels by both RT-PCR and Western blot analysis, as mRNA levels may not always correlate with protein expression. Include cell lines with known high (MCF-7, Jurkat) and low EBAG9 expression as reference points .

Antibody specificity controls: Use multiple antibodies targeting different EBAG9 epitopes to confirm specificity of observed effects. Include isotype controls for all antibody-based experiments to rule out non-specific binding .

Knockout/knockdown controls: Generate EBAG9 knockout or knockdown (siRNA/shRNA) models alongside matched wild-type controls. For in vivo studies, EBAG9 knockout mice crossed with disease models (e.g., TRAMP mice for prostate cancer) provide valuable negative controls .

Rescue experiments: After EBAG9 knockdown or knockout, reintroduce wild-type or mutant EBAG9 to determine if observed phenotypes can be rescued, confirming specificity of EBAG9-dependent effects.

Pharmacological controls: When using inhibitors or drugs that might affect EBAG9 function or localization (e.g., Brefeldin A), include appropriate vehicle controls and dose-response analyses .

Cell type controls: Since EBAG9 functions may vary between cell types, include multiple cell lineages in your experimental design to determine cell-type specific versus general effects of EBAG9.

How does EBAG9 contribute to tumor immune escape mechanisms?

EBAG9 contributes to tumor immune escape through multiple mechanisms affecting both cancer cells and immune cells in the tumor microenvironment:

Cancer cell-intrinsic effects: EBAG9 expression in tumor cells suppresses T-cell infiltration into the tumor microenvironment, creating a physical barrier to immune surveillance. This may occur through modulation of chemokine expression or alteration of cellular adhesion molecules that facilitate T-cell trafficking .

Immune cell regulation: Within host immune cells, EBAG9 functions as a negative regulator of cytotoxic T-cell activity, limiting their ability to kill tumor cells. This dual functionality creates a potent immunosuppressive environment that promotes tumor growth .

Extracellular vesicle-mediated transfer: Recent research has identified a novel mechanism whereby EBAG9 can be transferred from cancer cells to surrounding T cells via extracellular vesicles. This intercellular transfer of EBAG9 may reprogram T cells to adopt a more immunosuppressive phenotype, further enhancing tumor escape from immune surveillance .

Collaboration with EMT regulators: EBAG9 interacts with TM9SF1, which regulates epithelial-mesenchymal transition (EMT) in cancer cells. The EMT process is known to contribute to immune evasion by altering the immunogenicity of cancer cells and promoting resistance to immune effector mechanisms .

Impact on antigen presentation: As a Golgi-resident protein involved in O-linked glycosylation, EBAG9 may influence the post-translational modification of proteins involved in antigen processing and presentation, potentially reducing tumor cell recognition by the immune system .

Experimental approaches to study these mechanisms include co-culture systems with tumor and immune cells, in vivo tumor models comparing wild-type and EBAG9-deficient backgrounds, and extracellular vesicle isolation and characterization techniques.

How do EBAG9 expression levels correlate with O-linked glycan patterns in cancer cells?

The relationship between EBAG9 expression and O-linked glycan patterns, particularly the Tn antigen, presents a complex and partially correlated pattern in cancer cells:

Variable correlation: Studies have shown that high endogenous EBAG9 expression correlates with increased surface expression of the Tn antigen (recognized by the 22-1-1 antibody) in some cell lines like MCF-7 and Jurkat, but this correlation is not universal across all cancer cell types .

Mechanistic link: EBAG9 functions as a Golgi-resident modulator of O-linked glycan expression. Overexpression of EBAG9 can lead to the generation of normally cryptic O-linked glycans, including the Tn antigen (αGalNAc), which is recognized by the 22-1-1 antibody. This suggests that EBAG9 may influence the glycosylation machinery in the Golgi apparatus .

Cell line variability: When examining multiple tumor cell lines by immunoblotting for EBAG9 and flow cytometry for the 22-1-1 antigen, researchers observed that some cell lines with high EBAG9 expression (like SiSo) showed only moderate 22-1-1 antigen expression, indicating that additional factors may regulate the expression of O-linked glycans .

Implications for cancer biology: Aberrant glycosylation, including expression of the Tn antigen, is frequently associated with neoplastic transformation. Understanding how EBAG9 contributes to these altered glycosylation patterns may provide insights into cancer development and progression .

To study this correlation experimentally, researchers should:

• Quantify EBAG9 expression by Western blot and RT-qPCR

• Analyze surface expression of Tn antigen by flow cytometry using multiple anti-Tn antibodies

• Perform glycomic profiling using mass spectrometry to comprehensively characterize O-glycan structures

• Manipulate EBAG9 expression through overexpression or knockdown and observe resulting changes in glycan patterns

What is known about EBAG9 interaction with TM9SF1 and its impact on epithelial-mesenchymal transition?

The interaction between EBAG9 and TM9SF1 (Transmembrane 9 Superfamily Member 1) represents an emerging area of research with significant implications for cancer progression:

Identification of interaction: TM9SF1 has been identified as a collaborative interactor of EBAG9 through protein interaction studies. This interaction appears to be functionally significant in regulating cellular processes relevant to cancer progression .

Regulation of EMT: The EBAG9-TM9SF1 interaction has been implicated in the regulation of epithelial-mesenchymal transition (EMT), a critical process in cancer invasion and metastasis. EMT involves the loss of epithelial characteristics and acquisition of mesenchymal properties, enabling cancer cells to become more mobile and invasive .

Potential molecular mechanisms: While the precise molecular mechanisms remain to be fully elucidated, the interaction likely influences signaling pathways involved in EMT regulation. TM9SF1 is a transmembrane protein that may function in protein trafficking or as a component of signaling complexes, suggesting that EBAG9 could modify TM9SF1 function through its role in Golgi-mediated glycosylation or protein processing .

Implications for cancer therapy: Understanding the EBAG9-TM9SF1 axis could reveal new therapeutic targets for inhibiting EMT and consequently reducing cancer invasion and metastasis. Disrupting this interaction might restore epithelial characteristics to cancer cells, potentially making them more susceptible to conventional therapies.

To investigate this interaction further, researchers could employ:

• Co-immunoprecipitation and proximity ligation assays to confirm and characterize the physical interaction

• Domain mapping to identify specific interaction regions

• EMT marker analysis (E-cadherin, vimentin, Snail, etc.) following manipulation of EBAG9 or TM9SF1

• Migration and invasion assays to assess functional consequences of disrupting the interaction

• In vivo metastasis models comparing outcomes with intact versus disrupted EBAG9-TM9SF1 interaction

Why might there be discrepancies between EBAG9 detection methods in research?

Discrepancies in EBAG9 detection across different methods can arise from several technical and biological factors:

Antibody specificity issues: The historical confusion between antibodies recognizing EBAG9 (e.g., Ab-1) versus those recognizing the Tn antigen (e.g., 22-1-1) has led to significant discrepancies in the literature. These antibodies produce distinctly different staining patterns in immunohistochemistry, with 22-1-1 staining mucus and secretions while Ab-1 does not .

Protein vs. mRNA detection: Studies using RT-PCR to detect EBAG9 mRNA may show different results compared to protein-based methods due to post-transcriptional regulation. The correlation between EBAG9 mRNA and protein levels should not be assumed without verification .

Subcellular localization challenges: As a predominantly Golgi-localized protein, EBAG9 detection may be affected by sample preparation methods that disrupt Golgi structure. Proper fixation and permeabilization protocols are critical for accurate detection .

Glycosylation state influence: The detection of EBAG9 may be influenced by its own glycosylation state or by glycosylation of interacting proteins, which can vary between cell types and physiological conditions.

Sensitivity thresholds: Different detection methods have varying sensitivity thresholds. For example, flow cytometry might detect low levels of surface expression that immunohistochemistry might miss.

To address these discrepancies, researchers should:

• Use multiple detection methods in parallel

• Clearly document which antibodies are used and their known specificities

• Include appropriate positive and negative controls

• Consider the subcellular localization of EBAG9 when designing experiments

• Validate findings using genetic approaches (e.g., EBAG9 knockout controls)

How can I differentiate between the effects of EBAG9 and Tn antigen expression in experimental systems?

To differentiate between EBAG9 and Tn antigen effects in experimental systems, implement these specialized approaches:

Genetic manipulation with glycosylation analysis:

• Generate EBAG9 knockout cell lines using CRISPR-Cas9 and analyze both EBAG9 protein absence (by Western blot) and Tn antigen expression (by flow cytometry with 22-1-1 antibody)

• Create cell lines with altered O-glycosylation pathways by targeting enzymes like T-synthase that extend O-glycans beyond the Tn structure, while maintaining normal EBAG9 expression

Targeted antibody selection:

• Use Ab-1 antibody to specifically detect EBAG9 protein

• Use 22-1-1 or other validated anti-Tn antibodies to detect the Tn antigen

• Always perform parallel experiments with both antibodies to distinguish their effects

Rescue experiments with domain mutants:

• After EBAG9 knockout, reintroduce either wild-type EBAG9 or mutant versions lacking specific functional domains

• Analyze which domains of EBAG9 are required for Tn antigen expression versus other EBAG9 functions

Functional segregation:

• Test Tn antigen directly (using purified or synthesized Tn-bearing structures) in functional assays

• Compare these results with those from manipulating EBAG9 expression

• Discrepancies between these approaches would indicate separate functional roles

Combined imaging techniques:

• Perform dual-label confocal microscopy with anti-EBAG9 and anti-Tn antibodies to visualize their potentially distinct subcellular distributions

• Use super-resolution microscopy to precisely map their spatial relationship

By systematically applying these approaches, researchers can distinguish which biological effects are attributable to EBAG9 protein functions versus those stemming from altered Tn antigen expression.

What are the limitations of current EBAG9 antibodies in research applications?

Current EBAG9 antibodies present several important limitations that researchers should consider when designing experiments:

Specificity challenges: Historical confusion between antibodies recognizing EBAG9 protein (Ab-1) versus those detecting the Tn antigen (22-1-1) has led to misinterpretation of results. These antibodies recognize different antigens but have been used interchangeably in literature, necessitating careful validation .

Cross-reactivity concerns: Some anti-EBAG9 antibodies may cross-react with structurally similar proteins or with different glycosylation states of the same protein. Comprehensive specificity testing against a panel of related proteins is rarely performed by manufacturers.

Limited application versatility: Many antibodies work well in certain applications (e.g., immunohistochemistry) but perform poorly in others (e.g., immunoprecipitation or flow cytometry). The literature shows inconsistent staining patterns across different techniques using the same antibody .

Batch-to-batch variability: Particularly with polyclonal antibodies, significant batch-to-batch variation occurs that may affect experimental reproducibility. Even monoclonal antibodies can show different performance characteristics between production lots.

Inadequate epitope mapping: For many commercial antibodies, the precise epitope recognized is poorly characterized, making it difficult to predict how protein modifications, conformational changes, or interaction with binding partners might affect antibody recognition.

Species cross-reactivity limitations: Many antibodies are developed against human EBAG9 and may have limited cross-reactivity with orthologues from experimental model organisms, complicating translational research.

To address these limitations, researchers should:

• Validate antibodies using positive and negative controls (including EBAG9 knockout samples)

• Use multiple antibodies targeting different epitopes when possible

• Confirm key findings with complementary non-antibody-based approaches

• Document detailed information about antibody source, catalog number, and lot in publications

• Consider developing new, better-characterized antibodies for specific research applications

How might extracellular vesicle-mediated transfer of EBAG9 influence tumor microenvironment?

Extracellular vesicle (EV)-mediated transfer of EBAG9 from cancer cells to surrounding cells represents an emerging mechanism that could significantly reshape the tumor microenvironment:

Intercellular communication pathway: Recent research has identified that EBAG9 can be transferred from cancer cells to surrounding T cells via extracellular vesicles, establishing a novel mechanism for tumor-immune cell communication .

Functional reprogramming of recipient cells: Upon transfer to T cells, EBAG9 may maintain its immunosuppressive function, potentially converting effector T cells into cells with diminished cytotoxic capacity. This horizontal transfer of protein could amplify the immunosuppressive effect beyond what would be possible through cancer cell-intrinsic EBAG9 expression alone .

Expanded radius of influence: Through EV-mediated transfer, cancer cells could extend their immunosuppressive influence beyond direct cell-cell contact, affecting immune cells throughout the tumor microenvironment and potentially in draining lymph nodes where T cell priming occurs .

Biomarker potential: EBAG9-containing EVs in circulation could serve as liquid biopsy biomarkers for tumors with high EBAG9 expression, potentially offering prognostic or predictive information.

Therapeutic targeting opportunities: Interrupting the packaging of EBAG9 into EVs or blocking EV uptake by immune cells could represent novel therapeutic strategies to enhance antitumor immune responses.

Research approaches to investigate this phenomenon include:

• Isolation and characterization of EVs from EBAG9-expressing cancer cells

• Tracking labeled EBAG9 transfer between cells using live imaging techniques

• Functional assessment of T cells following exposure to EBAG9-containing EVs

• Analysis of EV content in patient samples correlated with immune infiltration patterns

• Development of inhibitors targeting EBAG9 packaging into EVs or EV uptake

What is the relationship between EBAG9 expression and response to immunotherapy?

The relationship between EBAG9 expression and immunotherapy response represents an important frontier in cancer research, though limited data is currently available:

Theoretical correlation: Given EBAG9's dual immunosuppressive roles—inhibiting T-cell infiltration into tumors and limiting T-cell cytotoxicity—high EBAG9 expression might predict poor response to immunotherapies that rely on functional T cells, such as immune checkpoint inhibitors .

Potential predictive biomarker: EBAG9 expression levels in tumor tissue or detection of EBAG9-containing extracellular vesicles in circulation could potentially serve as biomarkers to predict which patients might benefit from immunotherapy, though this requires clinical validation .

Combination therapy rationale: Targeting EBAG9 through genetic knockdown, antibody blockade, or small molecule inhibitors could potentially enhance the efficacy of existing immunotherapies by removing an immunosuppressive barrier.

Variable impact across cancer types: The impact of EBAG9 on immunotherapy response likely varies across cancer types and subtypes, depending on the predominant immune evasion mechanisms at play in each context.

Research approaches to investigate this relationship should include:

• Retrospective analysis of EBAG9 expression in tumor samples from patients treated with various immunotherapies, correlating expression with clinical outcomes

• Preclinical models comparing immunotherapy efficacy in EBAG9-expressing versus EBAG9-knockout tumors

• Development of EBAG9 inhibition strategies that could be tested in combination with established immunotherapies

• Single-cell analyses to understand how EBAG9 expression in specific cellular compartments influences the tumor-immune ecosystem

• Prospective clinical trials incorporating EBAG9 assessment as an exploratory biomarker

How does EBAG9's role in glycosylation impact broader cellular functions in cancer?

EBAG9's involvement in glycosylation processes has far-reaching implications for cancer cell biology beyond its direct effects on immune evasion:

Protein trafficking and secretion: As a Golgi-resident protein, EBAG9 influences O-linked glycosylation, which plays critical roles in protein folding, stability, trafficking, and secretion. Alterations in these processes can affect multiple cellular pathways simultaneously, including those controlling growth, survival, and metastasis .

Cell adhesion and migration: O-linked glycans are important components of cell surface molecules involved in cell-cell and cell-matrix interactions. EBAG9-mediated changes in glycosylation patterns could alter adhesive properties of cancer cells, potentially influencing their invasive and migratory capabilities .

Receptor function modulation: Many growth factor receptors and signaling molecules are regulated by glycosylation. EBAG9-dependent glycosylation changes might alter receptor activation thresholds, ligand binding affinities, or receptor turnover rates, thereby modifying signaling pathway activities .

Stress response and adaptation: Aberrant glycosylation patterns, including expression of the Tn antigen, may represent adaptive responses to cellular stress conditions in the tumor microenvironment. EBAG9 could be part of a stress-response mechanism that helps cancer cells survive under adverse conditions .

Metabolic reprogramming: Glycosylation processes are intimately connected to cellular metabolism, as they utilize sugar nucleotides derived from metabolic pathways. EBAG9's influence on glycosylation could intersect with cancer metabolic reprogramming, potentially creating vulnerabilities that could be therapeutically targeted.

To investigate these broader impacts, researchers could:

• Perform global glycomic and proteomic profiling in EBAG9-manipulated cells

• Identify specific proteins whose glycosylation and function are altered by EBAG9

• Analyze changes in cellular behavior (adhesion, migration, signaling) following EBAG9 manipulation

• Investigate metabolic dependencies in cells with different EBAG9 expression levels

• Explore the relationship between EBAG9 expression and cellular responses to various stressors (hypoxia, nutrient deprivation, etc.)

What are the most promising directions for future EBAG9 antibody research?

Future EBAG9 antibody research holds significant promise in several key directions:

Development of more specific antibodies: Creating highly specific monoclonal antibodies that can distinguish between EBAG9 protein and Tn antigens will be crucial for accurate research and potential clinical applications. These next-generation antibodies should undergo rigorous validation across multiple techniques .

Therapeutic antibody development: Designing antibodies that specifically target EBAG9 protein to block its immunosuppressive functions could represent a novel immunotherapy approach. Such antibodies could potentially enhance anti-tumor immune responses, particularly in combination with existing checkpoint inhibitors .

Diagnostic applications: Developing standardized immunohistochemical protocols using well-characterized anti-EBAG9 antibodies could improve cancer classification and prognostication. This would require large-scale validation studies correlating EBAG9 expression with clinical outcomes .

Extracellular vesicle targeting: Creating antibodies that can detect or block EBAG9 in extracellular vesicles might provide both diagnostic tools for liquid biopsies and therapeutic agents to prevent EV-mediated immunosuppression .

Mechanism-based combination strategies: Understanding the precise mechanisms by which EBAG9 modulates glycosylation and immune function will inform rational combinations of anti-EBAG9 antibodies with other targeted therapies or conventional treatments.

Structure-function studies: Developing antibodies against specific functional domains of EBAG9 could help elucidate structure-function relationships and identify critical regions for therapeutic targeting.

As research progresses, integration of these approaches with emerging technologies like single-cell analysis, spatial proteomics, and in vivo imaging will accelerate our understanding of EBAG9 biology and its therapeutic potential in cancer treatment.